urlscan.io logo urlscan.io
SecurityTrails logo

endpts.com Open in urlscan Pro
108.138.36.63  Public Scan

Back to summary
Submitted URL: https://e.endpointsnews.com/t/t-l-vtutjtd-jhdldljikl-m/
Effective URL: https://endpts.com/atreca-lays-off-40-of-remaining-workers-as-it-seeks-strategic-alternatives/
Submission Tags: falconsandbox
Submission: On April 05 via api from US — Scanned from DE

Form analysis 1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Nikkei Biotechnology
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * Editorial Standards
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



November 15, 2023 07:23 AM EST
People


THREE MONTHS AF­TER BIG RE­OR­GA­NI­ZA­TION, AN­TI­BODY MAK­ER ATRE­CA IS BACK
WITH AN­OTH­ER ROUND OF LAY­OFFS


AMBER TONG

SENIOR EDITOR

Atre­ca is let­ting an­oth­er 40% of its staff go in a move ex­pect­ed to keep
it­self afloat through the first quar­ter of 2024 as it ex­plores strate­gic
al­ter­na­tives.

The biotech is fo­cused on ad­vanc­ing APN-497444, an an­ti­body-drug
con­ju­gate tar­get­ing a tu­mor-spe­cif­ic gly­can, through pre­clin­i­cal
test­ing. Its fund­ing needs for that pro­gram and oth­er fol­low-up AD­Cs,
cou­pled with cur­rent fi­nan­cial mar­ket con­di­tions, led to the de­ci­sion,
Atre­ca CEO John Or­win said.


UNLOCK THIS ARTICLE INSTANTLY BY BECOMING A FREE SUBSCRIBER.

You’ll get access to free articles each month, plus you can customize what
newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER


MORE LIKE THIS

 * Amy­lyx to vol­un­tar­i­ly with­draw ALS drug Re­lyvrio af­ter Phase 3 fail,
   will lay off around 70% April 4, 2024
 * Lon­za taps Siegfried leader Wolf­gang Wien­and as new CEO April 2, 2024
 * Three more I-Mab ex­ecs ex­it af­ter US/Chi­na op­er­a­tions split April 2,
   2024


TRENDING NOW


NO­VAR­TIS PLOTS NEW PLU­VIC­TO FIL­ING TIME­LINE AF­TER WAIT­ING FOR OVER­ALL
SUR­VIVAL RE­SULTS


US-CHI­NA TEN­SIONS THREAT­EN TO EN­SNARE AD­DI­TION­AL CHI­NESE BIO­PHAR­MA
CON­TRAC­TORS


AD­DI­TION­AL DRUG­MAK­ERS FLAG RISKS OF WORK­ING WITH WUXI AMID HEIGHT­ENED US
SCRUTI­NY


EX­CLU­SIVE: JIM WIL­SON START­UP GETS FDA GREEN LIGHT FOR FIRST TEST OF GENE
EDIT­ING IN BA­BIES


EX­PERTS AP­PLAUD AMY­LYX FOR KEEP­ING ITS PROMISE TO WITH­DRAW ALS DRUG
RE­LYVRIO AF­TER TRI­AL FAIL­URE


PAXLOVID DIDN’T SHORT­EN COVID SYMP­TOMS IN VAC­CI­NAT­ED ADULTS, FULL TRI­AL
RE­SULTS CON­FIRM

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Nikkei Biotechnology
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * Editorial Standards
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2024

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 3:30 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



POST-HOC 1-2 times a week



Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET



BREAKING NEWS ALERTS 2-3 times a week


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.